Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly somapacitan vs daily Norditropin in short-stature children born small for gestational age
2023-506830-66-00Phase 2Authorised
- Sponsor
- Novo Nordisk
- Start
- May 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 15
01
Overview
Phase 2, randomised trial of somapacitan in Small for gestational age (SGA) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Height velocity. Planned start May 2019; status: authorised.
02
Drugs
somapacitan
03
Conditions
Small for gestational age (SGA)
Beyond the preview
Go deeper on 2023-506830-66-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506830-66-00.